The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a huge mover today! About 1.21M shares traded hands or 12.04% up from the average. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has risen 24.86% since February 26, 2016 and is uptrending. It has outperformed by 14.44% the S&P500.
The move comes after 8 months positive chart setup for the $285.99M company. It was reported on Sep, 30 by Barchart.com. We have $4.23 PT which if reached, will make NASDAQ:IDRA worth $188.75 million more.
Analysts await Idera Pharmaceuticals Inc (NASDAQ:IDRA) to report earnings on November, 4. They expect $-0.12 earnings per share, down 20.00% or $0.02 from last year’s $-0.1 per share. After $-0.11 actual earnings per share reported by Idera Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.
According to Zacks Investment Research, “Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera’s proprietary drug candidates are designed to modulate Toll-like Receptors, the body’s first line of immune defense. Idera’s pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.”
Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.22, from 1.03 in 2016Q1. The ratio increased, as 9 funds sold all Idera Pharmaceuticals Inc shares owned while 15 reduced positions. 3 funds bought stakes while 27 increased positions. They now own 34.46 million shares or 16.20% less from 41.12 million shares in 2016Q1.
Alyeska Investment Gp L P has 845,780 shares for 0.01% of their US portfolio. Teachers has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Susquehanna Group Limited Liability Partnership has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). American Int Grp owns 51,253 shares or 0% of their US portfolio. Glenmede Na has 0% invested in the company for 2,175 shares. Rhumbline Advisers accumulated 88,364 shares or 0% of the stock. Architects, a New Jersey-based fund reported 6,350 shares. Moreover, Hollencrest Ltd Liability Co has 0.04% invested in Idera Pharmaceuticals Inc (NASDAQ:IDRA) for 177,570 shares. Blackrock Advisors Ltd Llc accumulated 0% or 40,602 shares. Vanguard Grp Inc Incorporated has 0% invested in the company for 3.58M shares. Broadfin Lc last reported 3.09M shares in the company. The Illinois-based Group Inc Inc One Trading Ltd Partnership has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). The North Carolina-based Fincl Bank Of America Corporation De has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Goldman Sachs Inc holds 0% or 34,030 shares in its portfolio. Pnc Financial Svcs Inc holds 0% or 227 shares in its portfolio.
Insider Transactions: Since May 12, 2016, the stock had 2 buys, and 0 sales for $63,008 net activity. Casey Mark J also bought $49,608 worth of Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Thursday, May 12. GERAGHTY JAMES A also bought $13,400 worth of Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Friday, May 13.
Another recent and important Idera Pharmaceuticals Inc (NASDAQ:IDRA) news was published by Fool.com which published an article titled: “Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015” on January 13, 2016.
IDRA Company Profile
Idera Pharmaceuticals, Inc., incorporated on August 24, 2005, is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.